VERAXA Partners with Ardigen on AI Cancer Discovery
ZURICH, Switzerland, July 13, 2026 VERAXA Biotech announced a strategic collaboration with AI-driven computational biology company Ardigen to accelerate...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ZURICH, Switzerland, July 13, 2026 VERAXA Biotech announced a strategic collaboration with AI-driven computational biology company Ardigen to accelerate...
SOUTH SAN FRANCISCO, California, USA, June 3, 2026 CytomX Therapeutics has announced a significant expansion of its strategic research...
SPRING HOUSE, Pa., Feb. 4, 2026 — Clinical-stage biotechnology company Third Arc Bio announced the closing of a $52...
